- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 17, 2013 | 06:41 PM EDT
We plan to continue building up our financial and technology positions over the coming weeks. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 17, 2013 | 04:34 PM EDT
We used the strength this week to take some profits in three model portfolio positions, and we added to two other holdings. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 17, 2013 | 10:07 AM EDT
There is some news on three of our model portfolio holdings. Here are the highlights. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Medivation Inc. (MDVN)
MDVN (NASDAQ:Drugs)
$47.53
-0.76
-1.57%
Today's Range: 47.27 - 48.99 |
MDVN Avg Daily Volume: 1,251,200
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 1,324,600 |
| YTD Performance: -5.61% |
| Open: $48.38 |
| Previous Close: $48.29 |
| 52 Week Range: $39.36 - $59.24 |
| Oustanding Shares: 74,976,902 |
| Market Cap: 3,620,634,598 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 9 | 8 | 8 | 8 |
| Moderate Buy | 1 | 1 | 1 | 0 |
| Hold | 3 | 3 | 3 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.54 | 1.58 | 1.58 | 1.55 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.23 | $-0.26 | $-1.04 | $0.48 |
| Number of Analysts | 11 | 12 | 10 | 11 |
| High Estimate | $-0.13 | $-0.05 | $-0.61 | $1.41 |
| Low Estimate | $-0.44 | $-0.42 | $-1.40 | $-0.43 |
| Prior Year | $-0.08 | $-0.06 | $-0.56 | $-1.04 |
| Growth Rate (Year over Year) | -210.30% | -326.39% | -85.71% | 145.98% |
MikeOinSATX: @TInaAlbano2 Every stock you've asked me about has taken off soon after- $MDVN $AEGR $TSRO $THRX. You've a good eye or a good informant. ;-)
21 hours ago from web
21 hours ago from web
MikeOinSATX: @TInaAlbano2 Not sure, $MDVN may be down due to anticipated competition from $BAYRY's recently approved Xofigo. $AEGR - Nice jump yesterday.
22 hours ago from web
22 hours ago from web
BIOTECH888: $MDVN XTANDI OS 4.8months VS. Bayers XOFIGO OS 2.8months
23 hours ago from Twitter for iPad
23 hours ago from Twitter for iPad
IPO_Alerts: Check out the most widely held #smallcaps $MDVN $PLT $MTOR $UHT $ONXX $CPX $CAVM $PSSI $CNQR $MASI $BEXP http://t.co/FwFB9lfQEu
1 day ago from web
1 day ago from web
DanielMaika: @Jan_Kud $MDVN weekly/daily deathcross breakdown completed yday, Target 30$ by NOV, hehe #PUTS
1 day ago from web
1 day ago from web
Mind__Equity: Check out the most widely held #smallcaps $MDVN $AIR $ULTI $CYMI $DMND $POL $IPXL $PSSI $GEO $CROX $WCC http://t.co/6uWd3wL70d
2 days ago from web
2 days ago from web
janechin: @Quantumandlotus we will see next week! I don't really care about the $mdvn downgrade :)
2 days ago from Tweet Button
2 days ago from Tweet Button
Quantumandlotus: @janechin $mdvn could be trading side ways but looks like it can go ether way right now. :)
2 days ago from web
2 days ago from web
Medivation rated new Buy at Needham
MDVN was initiated with a Buy rating, Needham said. Xtandi is rapidly gaiing market share for the treatment of prostate cancer.
Medivation rated new Neutral at UBS
MDVN was initiated with a Neutral rating, UBS said. $59 price target. Xtandi should drive conversion to profitability, but peak expectations high.
Medivation numbers raised at Jefferies
Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating.
Adam Feuerstein, Sr. Columnist for TheStreet, says biotech earnings are the next big things to watch in biotech.
Medivation numbers raised at Citigroup
Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating.
Motivated CEOs, innovative products and smart deals count more than macro events.
Medivation numbers raised at Jefferies
Shares of MDVN now seen reaching $122, Jefferies said. Estimates also raised on Xtandi approval. Buy rating.
Medivation estimates, target raised at Credit Suisse
Shares of MDVN now seen reaching $149, according to Credit Suisse. Estimates also increased, given the earlier-than-expected approval of Xtandi. Outperform rating.
Medivation estimates, target cut at Credit Suisse
Shares of MDVN now seen reaching $120, according to Credit Suisse. Estimates also reduced, given rising operating costs. Outperform rating.
These mid-caps are volatile, but a merger or major announcement could send them soaring.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.